GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently undervalued according to InvestingPro Fair Value metrics, has reached a ...
Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...
Hosted on MSN22d
Depemokimab reviewed for asthma and CRSwNP in Asiaa new biologic treatment for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab would be the first biologic of its kind to offer a six ...
The following is a summary of “Unveiling the Prevalence and Impact of Silent Rhinovirus Infection in Chronic Rhinosinusitis with Nasal Polyps,” published in the January 2025 issue of Annals of Allergy ...
Concerning CRSwNP, GSK intends to secure approval in ... If approved, depemokimab will be the first ultra-long-acting biologic that requires the administration of only one dose every six months.
CRSwNP is a chronic condition that affects up to 4% of the ... With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, we are focused on ...
13 CRSwNP is a chronic condition that affects up to 4% of the ... With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, we are focused on ...
About Asthma, CRSwNP and type 2 inflammation ... With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, we are focused on improving ...
LONDON - GSK plc (LSE/NYSE: LON:GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback